Viva congratulations to Andrew Eustace
4 May 2017
Congratulations to Andrew Eustace who passed his PhD viva with minor corrections on April 24th 2017.
Andrew’s research, supervised by Dr Jim Middleton and Dr Angela Nobbs, focussed on syndecan-3 (a heparan sulfate proteoglycan) and inflammation.
A major function of the syndecan family is to present chemo-attractants to circulating white blood cells, helping direct them to sites of inflammation. Andrew’s thesis assessed how the endothelial expression of syndecan-3 varies in response to an inflammatory stimulus, the use of syndecan-3 as a biomarker in rheumatoid arthritis and also the potential of soluble syndecan-3 as a novel anti-inflammatory agent.
Andrew has been accepted for a post-doc at INSERM Paris, and departs Bristol on the 11th of May.